CRISPR Therapeutics CRSP Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | -18,933.6%-17,683pp | -1,250.4%— | —— | -56,190.4%— | |
| Net margin | -16,569.8%-15,588pp | -981.5%— | —— | -54,271.7%— | |
| EBITDA margin | -18,378.7%-17,180pp | -1,198.8%— | —— | -54,172.7%— | |
| Free cash flow margin | -9,855.5%-9,468pp | -387.7%-315pp | -72.7%+44,412pp | -44,484.9%— | |
| Returns | |||||
| Return on equity | -30.2%-11.0pp | -19.2%— | —— | -30.4%— | |
| Return on assets | -25.8%-9.4pp | -16.4%— | —— | -26%— | |
| Return on invested capital | -36.5%-10.5pp | -26%— | —— | -37.3%— | |
| Efficiency | |||||
| Asset turnover | 0×0.0× | 0×-0.1× | 0.2×+0.2× | 0×-0.4× | |
| Liquidity | |||||
| Current ratio | 13.3×-8.8× | 22.1×+4.5× | 17.5×+2.2× | 15.3×-4.9× | |
| Quick ratio | 13.3×-8.8× | 22.1×+4.5× | 17.5×+2.2× | 15.3×-4.9× | |
| Cash ratio | 2.3×-1.1× | 3.4×-0.2× | 3.6×+1.8× | 1.7×-5.9× | |
| Leverage | |||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | |||||
| Book value per share | $21.37-6.7% | $22.90-3.6% | $23.77-1.5% | $24.12-19.2% | |
| Valuation | |||||
| Market capitalization | $5B+48.8% | $3.36B-32.4% | $4.97B+56.2% | $3.18B-45.1% | |
| Enterprise value | $4.86B+47.8% | $3.28B-31.9% | $4.82B+50.0% | $3.21B-37.0% | |
| Price / sales | 1,423.8×+1,334× | 90×+76.6× | 13.4×-2,643× | 2,656.6×+2,650× | |
| Price / book | 2.6×+0.9× | 1.7×-0.9× | 2.6×+0.9× | 1.7×-0.7× | |
| EV / sales | 1,383.7×+1,296× | 88×+75.0× | 13×-2,670× | 2,683.5×+2,678× | |
| Free cash flow yield | -6.9%-2.6pp | -4.3%+1.1pp | -5.4%+11.3pp | -16.7%— | |
| Earnings yield | -11.6%-0.7pp | -10.9%— | —— | -20.4%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do CRISPR Therapeutics's ratios come from?
- Every ratio is computed from CRISPR Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
